Needham Maintains Buy on Cormedix, Raises Price Target to $15

Benzinga Newsdesk www.benzinga.com Positive 65.1%

Neg 0% Neu 0% Pos 65.1%

Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and raises the price target from $14 to $15.

Comments

No comments yet. Be the first!